Close Menu

This article has been updated from a previous version to include information about Japanese reimbursement for Invivoscribe's assay.

NEW YORK (GenomeWeb) – The US Food and Drug Administration said on Wednesday that it has approved an expanded indication for Invivoscribe Technologies' LeukoStrat CDx FLT3 Mutation Assay.

Specifically, FDA expanded approval for LeukoStrat for use with Xospata (gilteritinib), an Astellas Pharma drug for the treatment of adult patients who have relapsed or refractory acute myeloid leukemia with a FLT3 mutation.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

CBS This Morning highlights recent Medicare fraud involving offers of genetic testing.

Researchers find that many cancer drugs in development don't work quite how their developers thought they did, as Discover's D-brief blog reports.

Mariya Gabriel, a Bulgarian politician, is to be the next European Union research commissioner, according to Science.

In Science this week: a survey indicates that US adults are more likely to support the agricultural use of gene drives if they target non-native species and if they are limited, and more.